References
- Clayton, A. H., Althof, S. E., Kingsberg, S., Derogatis, L. R., Kroll, R., Goldstein, I., Kaminsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D. J. (2016). Bremelanotide for female sexual dysfunction in premenopausal women: A randomized, placebo-controlled dose-finding trial. Journal of Women’s Health, 12(3), 325–337. https://doi.org/https://doi.org/10.2217/whe-2016-0018
- Derogatis, L., Clayton, A., Lewis-D’Agostino, D., Wunderlich, G., & Fu, Y. (2008). Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. The Journal of Sexual Medicine, 5(2), 357–364. https://doi.org/https://doi.org/10.1111/j.1473-6109.2007.00672.x
- Kingsberg, S. A., & Althof, S. E. (2011). Satisfying sexual events as outcome measures in clinical trials of female sexual dysfunction. Journal of Sexual Medicine, 8(12), 3260–3270. https://doi.org/https://doi.org/10.1111/j.1743-6109.2011.02447.x
- Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics and Gynecology, 134(5), 899–908. https://doi.org/https://doi.org/10.1097/AOG.0000000000003500
- Revicki, D. A., Clayton, A. H., Stouch, B. C., Portman, D. J., Kingsberg, S. A., Derogatis, L. R., & Jordan, R. (2018). Developing clinically meaningful responder thresholds for primary endpoints for clinical trials in premenopausal women with hypoactive sexual desire disorder [ Presentation]. International Society for CNS Trials and Methodology, Washington, DC.
- Rosen, R., Brown, C., Heiman, J., Leiblum, S., Meston, C., Shabsigh, R., Ferguson, R., & D’Agostino, R. (2000). The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy, 26(2), 191–208. https://doi.org/https://doi.org/10.1080/009262300278597
- Spielmans, G. I. (2021, March 7). Re-analyzing phase III bremelanotide trials for “hypoactive sexual desire disorder” in women. Journal of Sex Research, 1–20. https://doi.org/https://doi.org/10.1080/00224499/2021.1885601
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). (2016). Low sexual interest/desire, and/or arousal in women: Developing drugs for treatment: Guidance for industry (Docket Number: FDA-2016-D-2817). Federal Register.